Lionco Pharmaceutical Group Co.,Ltd.

Shanghai Stock Exchange 603669.SS

Lionco Pharmaceutical Group Co.,Ltd. Interest Coverage Ratio for the year ending December 31, 2023: -37.80

Lionco Pharmaceutical Group Co.,Ltd. Interest Coverage Ratio is -37.80 for the year ending December 31, 2023, a -19.99% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Lionco Pharmaceutical Group Co.,Ltd. Interest Coverage Ratio for the year ending December 31, 2022 was -31.51, a -677.90% change year over year.
Lionco Pharmaceutical Group Co.,Ltd. Interest Coverage Ratio for the year ending December 31, 2021 was 5.45, a -70.25% change year over year.
Lionco Pharmaceutical Group Co.,Ltd. Interest Coverage Ratio for the year ending December 31, 2020 was 18.33, a 0.64% change year over year.
Lionco Pharmaceutical Group Co.,Ltd. Interest Coverage Ratio for the year ending December 31, 2019 was 18.21, a -81.16% change year over year.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

Shanghai Stock Exchange: 603669.SS

Lionco Pharmaceutical Group Co.,Ltd.

CEO	Ms. Ling Ping Tao
IPO Date	May 28, 2015
Location	China
Headquarters	Commercial and Residential Building 2
Employees	475
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Lionco Pharmaceutical Group Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in China. The company offers nutrition, antimicrobial, antiviral, digestion, cardiovascular, detoxification, anti-tumor, and other products. It also operates research institutes that specialize in the research of chemical drugs, natural medicines, and biological drugs. Lionco Pharmaceutical Group Co., Ltd. was founded in 2003 and is based in Shannan, China.

Key trends

Past 5 years